EFFECT OF COWANIN ON CYCLIN D1 EXPRESSION IN MCF-7/HER2 BREAST CANCER CELLS

Q2 Pharmacology, Toxicology and Pharmaceutics International Journal of Applied Pharmaceutics Pub Date : 2024-02-15 DOI:10.22159/ijap.2024.v16s1.32

D. Hefni, Dachriyanus, Angelica Maysya Nahda, F. Wahyuni

{"title":"EFFECT OF COWANIN ON CYCLIN D1 EXPRESSION IN MCF-7/HER2 BREAST CANCER CELLS","authors":"D. Hefni, Dachriyanus, Angelica Maysya Nahda, F. Wahyuni","doi":"10.22159/ijap.2024.v16s1.32","DOIUrl":null,"url":null,"abstract":"Objective: Cowanin, isolated from the stem bark of Asam kandis (Garcinia cowa Roxb.) has been known to have cytotoxic activity in MCF-7/HER2 breast cancer cells. Recent studies have reported that cowanin compounds can inhibit MCF-7/HER2 cell migration and the T47D cell cycle in the G0-G1 phase. This research aims to determine the effect of cowanin on the cyclin D1 protein expression in MCF-7/HER2 breast cancer cells. \nMethods: The treatment consisted of a negative control group and a group given cowanin at a concentration of IC50 value (10,51 µM). The expression of cyclin D1 protein was detected using the western blot method. Observations of protein area and density were carried out using ImageJ software. Data were analyzed using the independent T-test. \nResults: The research showed that cowanin compounds induced cell cycle arrest of MCF-7/HER2 breast cancer cells by reducing the expression of cyclin D1 protein (p<0,05). \nConclusion: The findings show that cowanin can significantly decrease the area and density of cyclin D1 protein","PeriodicalId":13737,"journal":{"name":"International Journal of Applied Pharmaceutics","volume":"20 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Applied Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ijap.2024.v16s1.32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Cowanin, isolated from the stem bark of Asam kandis (Garcinia cowa Roxb.) has been known to have cytotoxic activity in MCF-7/HER2 breast cancer cells. Recent studies have reported that cowanin compounds can inhibit MCF-7/HER2 cell migration and the T47D cell cycle in the G0-G1 phase. This research aims to determine the effect of cowanin on the cyclin D1 protein expression in MCF-7/HER2 breast cancer cells. Methods: The treatment consisted of a negative control group and a group given cowanin at a concentration of IC50 value (10,51 µM). The expression of cyclin D1 protein was detected using the western blot method. Observations of protein area and density were carried out using ImageJ software. Data were analyzed using the independent T-test. Results: The research showed that cowanin compounds induced cell cycle arrest of MCF-7/HER2 breast cancer cells by reducing the expression of cyclin D1 protein (p<0,05). Conclusion: The findings show that cowanin can significantly decrease the area and density of cyclin D1 protein

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

牛黄素对 mcf-7/her2 乳腺癌细胞中细胞周期蛋白 d1 表达的影响

目的：从 Asam kandis（Garcinia cowa Roxb.）茎皮中分离出的 Cowanin 对 MCF-7/HER2 乳腺癌细胞具有细胞毒性活性。最近有研究报告称，牛黄苷化合物可抑制 MCF-7/HER2 细胞迁移和 G0-G1 期的 T47D 细胞周期。本研究旨在确定cowanin对MCF-7/HER2乳腺癌细胞中细胞周期蛋白D1表达的影响。研究方法处理包括阴性对照组和给予 IC50 值（10.51 µM）浓度的 cowanin 组。用 Western 印迹法检测细胞周期蛋白 D1 蛋白的表达。使用 ImageJ 软件观察蛋白质的面积和密度。数据采用独立 T 检验进行分析。结果研究表明，牛磺酸化合物通过降低细胞周期蛋白 D1 的表达，诱导 MCF-7/HER2 乳腺癌细胞的细胞周期停滞（p<0.05）。结论研究结果表明，Cowanin 能显著降低细胞周期蛋白 D1 的表达面积和密度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Applied Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

1.40

自引率

0.00%

发文量

219

期刊介绍： International Journal of Applied Pharmaceutics (Int J App Pharm) is a peer-reviewed, bimonthly (onward March 2017) open access journal devoted to the excellence and research in the pure pharmaceutics. This Journal publishes original research work that contributes significantly to further the scientific knowledge in conventional dosage forms, formulation development and characterization, controlled and novel drug delivery, biopharmaceutics, pharmacokinetics, molecular drug design, polymer-based drug delivery, nanotechnology, nanocarrier based drug delivery, novel routes and modes of delivery; responsive delivery systems, prodrug design, development and characterization of the targeted drug delivery systems, ligand carrier interactions etc. However, the other areas which are related to the pharmaceutics are also entertained includes physical pharmacy and API (active pharmaceutical ingredients) analysis. The Journal publishes original research work either as a Original Article or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication in the Journal.